ActiveSight Signs Multi-Target Crystallography Service Agreement With Lexicon Pharmaceuticals, Inc.
Published: Jan 05, 2007
"We are delighted that Lexicon Pharmaceuticals has decided to expand their relationship with ActiveSight. We look forward to providing continued structural biology support for Lexicon's drug discovery programs," stated Duncan McRee, President of ActiveSight.
ActiveSight(TM) offers full gene-to-structure protein crystallography services, including fragment-based screening utilizing the Rigaku FR-E SuperBright(TM) generator and the ACTOR(TM) automation system. For more information visit www.active-sight.com.
ActiveSight and ACTOR are trademarks of Rigaku.